↵ Derman DP, Browde S, Kessel IL et al. Adjuvant chemotherapy (CMF) for stage III breast cancer: a randomized trial. Int J Radiat Oncol Biol Phys 1989 ; 17 : 257 –261.Derman DP.Adjuvent chemotherapy(CMF) for stage Ⅲ breast cancer:a randomized trial. International Journal of ...
CONCLUSION: BCT was better choice than MT for women with stage I or stage II breast cancer. 展开 关键词: breast conservation therapy, breast neoplasms, mastectomy, meta-analysis, randomized controlled DOI: 10.1093/annonc/mdm573 被引量: 46 年份: 2008 ...
Afatinib, an irreversible ErbB-family blocker, could improve the survival of advanced epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer patients (NSCLCm+). This phase II trial (NCT04201756) aimed to assess the feasibility of neoadjuvant Afatinib treatment for stage III NSCLC...
Results Triple-negative breast cancer was associated with younger age at diagnosis (56 vs 60 years; P = .001), larger tumors (2.1 vs 1.8 cm; P < .001), more stage II vs I cancer (42.1% vs 33.6%; P = .005), and more G3 tumors (86.4% vs 28.4%; P < .001...
William J. Gradishar, MD, highlights the inclusion of abemaciclib in the NCCN Guidelines for select high-risk early-stage breast cancer patients, anticipates the potential for ribociclib to secure a similar guideline position, and emphasizes the importan
So we say that cancer patients can not be ignored three Kang stage, had the lesson of blood, can not tolerate the slightest. The core of these three stages can not be separated from hard practice. Through the practice of Qigong, the complete recovery three gradual process, a process is a...
Objective: To define the optimal treatment for women with stage III or locally advanced breast cancer (LABC). Evidence: Systematic review of English-language literature retrieved from MEDLINE (1984 to June 2002) and CANCERLIT (1983 to June 2002). A nonsystematic review of the literature was con...
To introduce the advances of breast-conserving therapy(BCT) of early stage breast cancer.Discussion of pathological and biological feature of breast cancer... D Pang - 《China Oncology》 被引量: 4发表: 2005年 Results of Breast-Conserving Therapy for Early Stage Breast Cancer This study evaluated...
This Phase III trial is conducted in a fully remote setting and enrolls young adult couples (current age 18–44 years) with a history of breast or gynecologic cancer (stage 1–4, diagnosed under age 40) within the past 6 months to 5 years. Eligible dyads are recruited from across the ...
33% vs. 22%). Further analysis TNBC patients showed that pCR rates were 51% and 26% in the veliparib–carboplatin group and the control group, respectively. Nevertheless, studies on the addition of veliparib to carboplatin and standard chemotherapy in stage IIb–IIIc breast cancer and TNBC (NC...